Michele Maio Selected Research

tremelimumab

1/2021	Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study.
8/2020	Permanent diabetes insipidus in a patient with mesothelioma treated with immunotherapy.
2/2020	Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival.
1/2018	Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.
1/2017	Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
4/2015	Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.
1/2015	CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?
1/2014	Immune checkpoint blockade in malignant mesothelioma: A novel therapeutic strategy against a deadly disease?
10/2013	Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
2/2013	Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michele Maio Research Topics

Disease

111	Melanoma (Melanoma, Malignant) 10/2022 - 01/2002
103	Neoplasms (Cancer) 01/2022 - 01/2002
17	Neoplasm Metastasis (Metastasis) 01/2022 - 01/2002
16	Testicular Neoplasms (Testicular Cancer) 12/2021 - 01/2002
12	Disease Progression 01/2021 - 02/2003
11	Mesothelioma 12/2021 - 03/2013
10	Malignant Mesothelioma 10/2019 - 10/2013
7	Brain Neoplasms (Brain Tumor) 01/2022 - 10/2010
6	Colitis 11/2020 - 06/2014
6	Body Weight (Weight, Body) 10/2019 - 06/2011
5	Fatigue 01/2017 - 06/2011
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 01/2020
4	COVID-19 01/2022 - 01/2020
4	Lymphatic Metastasis 01/2019 - 10/2010
4	Exanthema (Rash) 01/2018 - 06/2011
4	Hematologic Neoplasms (Hematological Malignancy) 10/2005 - 02/2003
3	Microsatellite Instability 01/2022 - 01/2022
3	Hypophysitis 08/2020 - 01/2017
3	Keratoacanthoma 01/2018 - 06/2011
3	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2018 - 06/2011
3	Nausea 01/2017 - 06/2011
3	Neutropenia 04/2015 - 03/2014
3	Diarrhea 02/2013 - 06/2011
2	Pneumonia (Pneumonitis) 10/2021 - 11/2020
2	Colonic Neoplasms (Colon Cancer) 11/2020 - 01/2018
2	Arthralgia (Joint Pain) 01/2018 - 06/2011
2	Prostatic Neoplasms (Prostate Cancer) 12/2017 - 06/2014
2	Thrombocytopenia (Thrombopenia) 04/2015 - 07/2014
2	Pruritus (Itching) 01/2015 - 02/2013
2	Renal Cell Carcinoma (Grawitz Tumor) 03/2013 - 08/2002

Drug/Important Bio-Agent (IBA)

48	IpilimumabIBA 10/2022 - 08/2009
30	AntigensIBA 12/2021 - 01/2002
21	Monoclonal AntibodiesIBA 01/2022 - 02/2002
17	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2014
17	AntibodiesIBA 01/2018 - 03/2002
16	NivolumabIBA 10/2022 - 01/2015
13	Biomarkers (Surrogate Marker)IBA 01/2021 - 12/2008
13	DNA (Deoxyribonucleic Acid)IBA 12/2019 - 01/2002
11	VemurafenibIBA 10/2021 - 06/2011
11	tremelimumabIBA 01/2021 - 10/2010
8	Proteins (Proteins, Gene)FDA Link 02/2020 - 02/2002
8	Decitabine FDA Link 01/2018 - 01/2002
8	Dacarbazine (DIC)FDA LinkGeneric 04/2015 - 04/2010
7	VaccinesIBA 01/2022 - 03/2002
6	Messenger RNA (mRNA)IBA 01/2018 - 02/2002
6	HLA Antigens (Human Leukocyte Antigens)IBA 06/2014 - 09/2003
5	pembrolizumabIBA 01/2022 - 11/2016
5	LigandsIBA 01/2022 - 10/2010
5	Pharmaceutical PreparationsIBA 10/2021 - 12/2011
5	cobimetinibIBA 10/2021 - 07/2012
5	Interleukin-2 (IL2)IBA 10/2021 - 03/2002
5	CytokinesIBA 01/2018 - 03/2002
5	Peptides (Polypeptides)IBA 01/2014 - 08/2006
5	Histocompatibility Antigens Class IIBA 03/2013 - 06/2003
4	guadecitabineIBA 12/2021 - 03/2013
4	durvalumabIBA 01/2021 - 01/2018
4	fotemustine (Muphoran)IBA 01/2021 - 10/2010
4	EndoglinIBA 04/2010 - 02/2003
3	MicroRNAs (MicroRNA)IBA 01/2022 - 06/2010
3	Immunoglobulin G (IgG)IBA 01/2022 - 03/2002
3	InterferonsIBA 01/2018 - 06/2009
3	Alanine Transaminase (SGPT)IBA 01/2018 - 04/2015
3	PlatinumIBA 01/2017 - 10/2013
3	Biological ProductsIBA 01/2017 - 03/2004
3	MART-1 AntigenIBA 08/2014 - 05/2012
3	HLA-DR Antigens (HLA-DR)IBA 03/2014 - 09/2003
3	Interferon-alpha (Interferon Alfa)IBA 10/2012 - 08/2006
3	Glycoproteins (Glycoprotein)IBA 06/2011 - 02/2002
3	Histones (Histone)IBA 06/2010 - 09/2003
3	Heat-Shock Proteins (Heat-Shock Protein)IBA 08/2006 - 10/2002
3	Complement System Proteins (Complement)IBA 06/2004 - 02/2002
2	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 10/2021 - 01/2021
2	B7-H1 AntigenIBA 02/2020 - 10/2017
2	dehydroacetic acid (DHAS)IBA 12/2019 - 01/2018
2	RNA (Ribonucleic Acid)IBA 10/2019 - 01/2019
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2019 - 11/2014
2	ThymalfasinIBA 01/2018 - 04/2010
2	CTLA-4 AntigenIBA 01/2017 - 07/2015
2	Interleukin-4 (Interleukin 4)IBA 08/2014 - 03/2002
2	dabrafenibIBA 05/2014 - 07/2012
2	Neoplasm Antigens (Tumor Antigens)IBA 03/2014 - 06/2013
2	NucleotidesIBA 01/2014 - 05/2011
2	HLA-A*02:01 antigenIBA 05/2013 - 10/2010
2	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 03/2013 - 06/2007
2	Temozolomide (Temodar)FDA LinkGeneric 02/2013 - 10/2010
2	Cancer VaccinesIBA 12/2012 - 03/2008
2	Cytotoxins (Cytolysins)IBA 10/2010 - 12/2009
2	vitespinIBA 08/2006 - 10/2002
2	Histocompatibility Antigens Class IIIBA 08/2004 - 09/2003
2	Transforming Growth Factor beta Receptors (TGF beta Receptors)IBA 09/2003 - 02/2003
1	Circular RNAIBA 01/2022
1	trametinibIBA 01/2022
1	triplex DNA (H-DNA)IBA 01/2022

Therapy/Procedure

53	Therapeutics 01/2022 - 09/2003
45	Immunotherapy 12/2021 - 01/2002
14	Biological Therapy 07/2021 - 06/2004
10	Drug Therapy (Chemotherapy) 11/2020 - 08/2009
3	Radiotherapy 01/2022 - 10/2010
3	Retreatment 01/2021 - 01/2014
3	Intravenous Infusions 01/2019 - 01/2017